Ophthalmology in 2025: Year in Review

Plenty of major decisions from the US Food and Drug Administration (FDA) and key trial results have punctuated 2025 for ophthalmology, making it a wildly productive year for the industry. Everything from diabetic retinopathy (DR) to diabetic macular edema (DME) was addressed at some point, with crucial drugs like Susvimo and Acoltremon Ophthalmic Solution receiving approval to enter US markets. Treatment pipelines with Nanoscope and eSight also made significant progress this past year, as detailed in episodes of New Insight with Veeral Sheth, MD.